Glycosphingolipids and kidney disease

Advances in Experimental Medicine and Biology

Volumn 721, Issue , 2011, Pages 121-138

  Mather, Andrew R ^a   Siskind, Leah J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GANGLIOSIDE GD 1A; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GENZ 123346; GLYCOSPHINGOLIPID; SIALIDASE; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ALPHA GALACTOSIDASE A GENE; ARTICLE; CELLULAR DISTRIBUTION; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENZYME INACTIVATION; FABRY DISEASE; FOCAL GLOMERULOSCLEROSIS; GENE; GENE MUTATION; GLUCOSE METABOLISM; HUMAN; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LIPID ANALYSIS; LIPID METABOLISM; LIPID TRANSPORT; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; METABOLIC SYNDROME X; MINIMAL CHANGE GLOMERULONEPHRITIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT; CERAMIDES; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; FABRY DISEASE; GLOMERULONEPHRITIS; GLYCOSPHINGOLIPIDS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY NEOPLASMS; METABOLIC SYNDROME X; MICE; POLYCYSTIC KIDNEY DISEASES; RATS;

ANIMALIA;

EID: 80053589085     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0650-1_8     Document Type: Article

References (190)

1. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9(2):139-150. (Pubitemid 351158911)
2. Clarke CJ, Snook CF, Tani M et al. The extended family of neutral sphingomyelinases. Biochemistry 2006; 45(38):11247-11256. (Pubitemid 44453973)
3. Smith EL, Schuchman EH. The unexpected role ofacid sphingomyelinase in cell death and the pathophysiology ofcommondiseases. FASEBJ2008;22(10):3419- 3431.
4. Menaldino DS, Bushnev A, Sun A et al. Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action. Pharmacol Res 2003; 47(5):373-381. (Pubitemid 36379199)
5. Perry DK. Serine palmitoyltransferase: role in apoptotic de novo ceramide synthesis and other stress responses. Biochim Biophys Acta 2002; 1585(2-3):146-152. (Pubitemid 36092079)
6. Mandon EC, Ehses I, Rother J et al. Subcellular localization and membrane topology of serine palmitoyltransferase, 3-dehydrosphinganine reductase and sphinganine N-acyltransferase in mouse liver. J Biol Chem 1992; 267(16):11144-11148.
7. Mao C, Obeid LM. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine and sphingosine-1-phosphate. Biochim Biophys Acta 2008; 1781(9):424-434.
8. Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do lasses (longevity assurance genes) become CerS (ceramide synthases)?. Insights into the regulation of ceramide synthesis. J Biol Chem 2006; 281(35): 25001-25005. (Pubitemid 44401887)
9. RiebelingC, Allegood JC, WangEet al. Two mammalian longevity assurance gene (LAGl)family members, trhl and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J Biol Chem 2003; 278(44):43452-43459. (Pubitemid 37345968)
10. Mizutani Y, Kihara A, Igarashi Y. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J 2005; 390(Pt 1):263-271. (Pubitemid 41192252)
11. Schiffmann S, Ziebell S, Sandner J et al. Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C16:0-ceramide. Biochem Pharmacol 80(11):1632-1640.
12. Pewzner-Jung Y, Brenner O, Braun S et al. A critical role for ceramide synthase 2 in liver homeostasis: II. Insights into molecular changes leading to hepatopathy. J Biol Chem 285(14):10911-10923.
13. Pewzner-Jung Y, Park H, Laviad EL et al. A critical role for ceramide synthase 2 in liver homeostasis: I. Alterations in lipid metabolic pathways. J Biol Chem 285(14):10902-10910.
14. Yacoub A, Hamed HA, Allegood J et al. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res 70(3):1120-1129.
15. Erez-Roman R, Pienik R, Futerman AH. Increased ceramide synthase 2 and 6 mRNA levels in breast cancer tissues and correlation with sphingosine kinase expression. Biochem Biophys Res Commun 391(1):219-223.
16. Imgrund S et al. Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration and hepatocarcinomas. J Biol Chem 2009; 284(48):33549-33560.
17. Sridevi P, Alexander H, Laviad EL et al. Stress-induced ER to Golgi translocation of ceramide synthase 1 is dependent on proteasomal processing. Exp Cell Res 316(1):78-91.
18. Senkal CE, Ponnusamy S, Bielawski J et al. Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation ofthe ATF6/CHOP arm of ER-stress-response pathways. FASEB J 24(1):296-308.
19. Sridevi P, Alexander H, Laviad EL et al. Ceramide synthase 1 is regulated by proteasomal mediated turnover. Biochim Biophys Acta 2009; 1793(7):1218-1227.
20. White-Gilbertson S, Mullen T, Senkal C et al. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene 2009; 28(8):1132-1141.
21. Min J, Mesika A, Sivaguru M et al. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol Cancer Res 2007; 5(8):801-812. (Pubitemid 47294808)
22. Xu Z, Zhou J, McCoy DM et al. LASS5 is the predominant ceramide synthase isoform involved in de novo sphingolipid synthesis in lung epithelia. J Lipid Res 2005; 46(6):1229-1238. (Pubitemid 43109837)
23. SpassievaSD, Mullen TD, TownsendDM et al. Disruption of ceramide synthesis by CerS2 down-regulation leads to autophagy and the unfolded protein response. Biochem J 2009; 424(2):273-283.
24. Taha TA, Mullen TD, Obeid LM. A house divided: ceramide, sphingosine and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta 2006; 1758(12):2027-2036. (Pubitemid 44879375)
25. Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 2006; 39(2):113-131.
26. Buton X, Herve P, Kubelt J et al. Transbilayer movement of monohexosylsphingolipids in endoplasmic reticulum and Golgi membranes. Biochemistry 2002; 41(43):13106-13115. (Pubitemid 35215796)
27. Halter D, Neumann S, van Dijk SM et al. Pre- and postGolgi translocation of glucosylceramide in glycosphingolipid synthesis. J Cell Biol 2007; 179(1):101-115. (Pubitemid 47606687)
28. Chatterjee S, Pandey A. The Yin and Yang of lactosylceramide metabolism: implications in cell function. Biochim Biophys Acta 2008; 1780(3):370-382.
29. Kolter T, Doering T, Wilkening G et al. Recent advances inthe biochemistry ofglycosphingolipidmetabolism. Biochem Soc Trans 1999; 27(4):409-415. (Pubitemid 29412459)
30. Memon RA, Holleran WM, Uchida Y et al. Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin. J Lipid Res 2001; 42(3):452-459. (Pubitemid 32270070)
31. Whitmore CD, Hindsgaul O, Palcic MM et al. Metabolic cytometry. Glycosphingolipid metabolism in single cells. Anal Chem 2007; 79(14):5139-5142. (Pubitemid 47121022)
32. Xu YH, Barnes S, Sun Y et al. Multi-system disorders of glycosphingolipid and ganglioside metabolism. J Lipid Res 51(7):1643-1675.
33. Degroote S, Wolthoorn J, van Meer G. The cell biology of glycosphingolipids. Semin Cell Dev Biol 2004; 15(4):375-387. (Pubitemid 38781900)
34. Morales A, Colell A, Mari M et al. Glycosphingolipids and mitochondria: role in apoptosis and disease. GlycoconjJ2004; 20(9):579-588.
35. Anastasia L, Papini N, Colazzo F et al. NEU3 sialidase strictly modulates GM3 levels in skeletal myoblasts C2C12 thus favoring their differentiation and protecting them from apoptosis. J Biol Chem 2008; 283(52):36265-36271.
36. Zanchetti G, Colombi P, Manzoni M et al. Sialidase NEU3 is a peripheral membrane protein localized on the cell surface and in endosomal structures. Biochem J 2007; 408(2):211-219. (Pubitemid 350206344)
37. Magesh S, Suzuki T, Miyagi T et al. Homology modeling ofhuman sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: hints for the design of selective NEU3 inhibitors. J Mol Graph Model 2006; 25(2):196-207. (Pubitemid 44345275)
38. Wang Y, Yamaguchi K, Wada T et al. A close association of the ganglioside-specific sialidase Neu3 with caveolin in membrane microdomains. J Biol Chem 2002; 277(29):26252-26259. (Pubitemid 34967114)
39. Monti E, BassiMT, Papini N et al. Identification and expression ofNEU3, anovelhuman sialidase associated to the plasma membrane. Biochem J 2000; 349(Pt 1):343-351. (Pubitemid 30440200)
40. Bigi A, Morosi L, Pozzi C et al. Human sialidase NEU4 long and short are extrinsic proteins bound to outer mitochondrial membrane and the endoplasmic reticulum, respectively. Glycobiology 20(2):148-157.
41. Yamaguchi K, Hata K, Koseki K et al. Evidence for mitochondrial localization of a novel human sialidase (NEU4). Biochem J 2005; 390(Pt 1):85-93. (Pubitemid 41192234)
42. Aerts JM, Hollak CE, Boot RG et al. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis 2006; 29(2-3):449-456. (Pubitemid 43880650)
43. Kolter T, Sandhoff K Sphingolipid metabolism diseases. Biochim Biophys Act. 2006; 1758 12: 2057-2079 (Pubitemid 44879358)
44. Lachmann RH. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders. Drugs Today (Barc) 2006; 42(1):29-38.
45. Ozkara HA. Recent advances in the biochemistry and genetics of sphingolipidoses. Brain Dev 2004; 26(8):497-505. (Pubitemid 39463340)
46. Platt FM et al. New developments in treating glycosphingolipid storage diseases. Adv Exp Med Biol 2005; 564:117-126.
47. Raas-Rothschild A, Pankova-Kholmyansky I, Kacher Y et al. Glycosphingolipidoses: beyond the enzymatic defect. GlycoconjJ2004; 21(6):295-304. (Pubitemid 39439980)
48. Sawkar AR, D'Haeze W, Kelly JW. Therapeutic strategies to ameliorate lysosomal storage disorders-a focus on Gaucher disease. Cell Mol Life Sci 2006; 63(10):1179-1192. (Pubitemid 43939004)
49. Sillence DJ. New insights into glycosphingolipid functions-storage, lipid rafts and translocators. Int Rev Cytol 2007; 262:151-189. (Pubitemid 47031308)
50. Brasitus TA, Schachter D. Lipid dynamics and lipid-protein interactions in rat enterocyte basolateral and microvillus membranes. Biochemistry 1980; 19(12):2763-2769.
51. Forstner GG, Tanaka K, Isselbacher KJ. Lipid composition of the isolated rat intestinal microvillus membrane. Biochem J 1968; 109(1):51-59.
52. Kawai K, Fujita M, Nakao M. Lipid components of two different regions of an intestinal epithelial cell membrane of mouse. Biochim Biophys Acta 1974; 369(2):222-233.
53. Stubbs CD, Ketterer B, Hicks RM. The isolation and analysis of the luminal plasma membrane of calf urinary bladder epithelium. Biochim Biophys Acta 1979; 558(1):58-72. (Pubitemid 10194344)
54. Fanzani A, Giuliani R, Colombo F et al. Overexpression of cytosolic sialidase Neu2 induces myoblast differentiation in C2C12 cells. FEBS Lett 2003; 547(1-3):183-188. (Pubitemid 36829402)
55. Monti E, Preti A, Nesti C et al. Expression of a novel human sialidase encoded by the NEU2 gene. Glycobiology 1999; 9(12):1313-1321. (Pubitemid 30011511)
56. Monti E, Preti A, Rossi E et al. Cloning and characterization of NEU2, a human gene homologous to rodent soluble sialidases. Genomics 1999; 57(1):137-143. (Pubitemid 29187946)
57. Young WW Jr, Lutz MS, Blackburn WA. Endogenous glycosphingolipids move to the cell surface at a rate consistentwithbulkflow estimates. JBiol Chem 1992; 267(17):12011-12015.
58. vanMeerG,LismanQ.Sphingolipidtransport:raftsandtranslocators. J Biol Chem2002;277(29):25855-25858. (Pubitemid 34967062)
59. Marks DL, Pagano RE. Endocytosis and sorting of glycosphingolipids in sphingolipid storage disease. Trends Cell Biol 2002; 12(12):605-613. (Pubitemid 35461860)
60. van Meer G, Stelzer EH, Wijnaendts-van-Resandt RW et al. Sorting of sphingolipids in epithelial (Madin-Darby canine kidney) cells. J Cell Biol 1987; 105(4):1623-1635.
61. Sharma DK, Choudhury A, Singh RD et al. Glycosphingolipids internalized via caveolar-related endocytosis rapidly merge with the clathrin pathway in early endosomes and form microdomains for recycling. J Biol Chem 2003; 278(9):7564-7572. (Pubitemid 36800764)
62. Singh RD, Puri V, Valiyaveettil JT et al. Selective caveolin-l-dependent endocytosis of glycosphingolipids. Mol Biol Cell 2003; 14(8):3254-3265.
63. Warnock DE, Lutz MS, Blackburn WA et al. Transport of newly synthesized glucosylceramide to the plasma membrane by a nonGolgi pathway. Proc Natl Acad Sci USA 1994; 91(7):2708-2712. (Pubitemid 24139417)
64. Lin X, Mattjus P, Pike HM et al. Cloning and expression of glycolipid transfer protein from bovine and porcine brain. J Biol Chem 2000; 275(7):5104-5110. (Pubitemid 30108911)
65. Gupta G, Surolia A. Glycosphingolipids in microdomain formation and their spatial organization. FEBS Lett 584(9):1634-1641.
66. Igarashi Y, Kannagi R. Glycosphingolipids as mediators ofphenotypic changes associated with development and cancer progression. J Biochem 147(1):3-8.
67. Sonnino S, AureliM, Loberto N et al. Fine tuning ofcell functions through remodeling of glycosphingolipids by plasma membrane-associated glycohydrolases. FEBS Lett 584(9):1914-1922.
68. Guan F, Handa K, Hakomori SI. Specific glycosphingolipids mediate epithelial-to-mesenchymal transition ofhuman and mouse epithelial cell lines. Proc Natl Acad Sci USA 2009; 106(18):7461-7466.
69. Jung JU, Ko K, Lee DH et al. The roles of glycosphingolipids in the proliferation and neural differentiation of mouse embryonic stem cells. Exp Mol Med 2009; 41(12):935-945.
70. Langeveld M, Aerts JM. Glycosphingolipids and insulin resistance. Prog Lipid Res 2009; 48(3-4):196-205.
71. Sonnino S et al. Role of very long fatty acid-containing glycosphingolipids in membrane organization and cell signaling: the model oflactosylceramide in neutrophils. Glycoconj J 2009; 26(6):615-621.
72. Wennekes T et al. Glycosphingolipids-nature, function and pharmacological modulation. Angew Chem Int Ed Engl 2009; 48(47):8848-8869.
73. Westerlund B, Slotte JP. How the molecular features of glycosphingolipids affect domain formation in fluid membranes. Biochim Biophys Acta 2009; 1788(1):194-201.
74. Takiar V, Caplan MJ. Telling kidneys to cease and decyst. Nat Med 16(7):751-752.
75. Gnewuch C, Jaques G, Havemann K et al. Re-assessment of acidic glycosphingolipids in small-cell-lung-cancer tissues and cell lines. Int J Cancer Suppl 1994; 8:125-126. (Pubitemid 24188974)
76. Hakomori S. New directions in cancer therapy based on aberrant expression of glycosphingolipids: anti-adhesion and ortho-signaling therapy. Cancer Cells 1991; 3(12):461-470.
77. Shida K, Misonou Y, Korekane H et al. Unusual accumulation of sulfated glycosphingolipids in colon cancer cells. Glycobiology 2009; 19(9):1018-1033.
78. Suzuki M, Ando O, Ohta T et al. High expression of glycosphingolipids involved in procoagulant activity ofcancercells. Oncol Rep 1999; 6(1):113-115. (Pubitemid 128532809)
79. Bieberich E. Integration of glycosphingolipid metabolism and cell-fate decisions in cancer and stem cells: review and hypothesis. Glycoconj J 2004; 21(6):315-327. (Pubitemid 39434560)
80. Cabot MC, Giuliano AE, Volner A et al. Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett 1996; 394(2):129-131. (Pubitemid 26341491)
81. Gouaze-Andersson V, Cabot MC. Glycosphingolipids and drug resistance. Biochim Biophys Acta 2006; 1758(12):2096-2103. (Pubitemid 44879371)
82. Gu Y, Zhang J, Mi W et al. Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells. Breast Cancer Res 2008; 10(1):R1.
83. Hakomori S. Cancer-associated glycosphingolipid antigens: their structure, organization and function. Acta Anat (Basel) 1998; 161(1-4):79-90. (Pubitemid 28478161)
84. Kovbasnjuk O, Mourtazina R, Baibakov B et al. The glycosphingolipid globotriaosylceramide in the metastatic transformation ofcolon cancer. Proc Natl Acad Sci USA 2005; 102(52):19087-19092. (Pubitemid 43049570)
85. Lavie Y et al. Agents that reverse multidrug resistance, tamoxifen, verapamil and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 1997; 272(3):1682-1687. (Pubitemid 27043253)
86. Messner MC, Cabot MC. Glucosylceramide in humans. Adv Exp Med Biol 688:156-164.
87. MiyagiT, WadaT, YamaguchiK. Roles of plasma membrane-associated sialidase NEU3 in human cancers. Biochim Biophys Acta 2008; 1780(3):532-537. (Pubitemid 351395305)
88. Morales A, Fernandez-Checa JC. Pharmacological modulation of sphingolipids and role in disease and cancer cell biology. Mini Rev Med Chem 2007; 7(4):371-382. (Pubitemid 46681760)
89. Radin NS. Chemotherapy by slowing glucosphingolipid synthesis. Biochem Pharmacol 1999; 57(6): 589-595. (Pubitemid 29081495)
90. Shida K, Korekane H, Misonou Y et al. Novel ganglioside found in adenocarcinoma cells of Lewis-negative patients. Glycobiology 20(12):1594-1606.
91. Zhang X, KiechleFL. Review: glycosphingolipids in health and disease. Ann Clin Lab Sci 2004; 34(1):3-13. (Pubitemid 38280300)
92. Chatterjee S, Wei H. Roles of glycosphingolipids in cell signaling: adhesion, migration and proliferation. Methods Enzymol 2003; 363:300-312. (Pubitemid 37267678)
93. Kimball PM, Hammonds L, McKibbin JM et al. In vitro effects of glycosphingolipids on human tumor cellproliferation. Proc Soc Exp BiolMed 1981; 166(1):107-112. (Pubitemid 11131827)
94. Bhunia AK, SchwarzmannG, Chatterjee S. GD3 recruits reactive oxygen species to induce cell proliferation and apoptosis in human aortic smooth muscle cells. J Biol Chem 2002; 277(19):16396-16402. (Pubitemid 34967650)
95. Nishio M, Tajima O, Furukawa K et al. Over-expression of GM1 enhances cell proliferation with epidermal growth factor without affecting the receptor localization in the microdomain in PC12 cells. Int J Oncol 2005; 26(1):191-199.
96. Pannu R, Singh AK, Singh I. A novel role of lactosylceramide in the regulation of tumor necrosis factor alpha-mediated proliferation ofrat primary astrocytes. Implications for astrogliosisfollowingneurotrauma. J Biol Chem 2005; 280(14):13742-13751. (Pubitemid 40517270)
97. Yanagisawa M, Liour SS, Yu RK. Involvement of gangliosides in proliferation of immortalized neural progenitor cells. J Neurochem 2004; 91(4):804-812. (Pubitemid 39507357)
98. Chatterjee S. Oxidized low density lipoproteins and lactosylceramide both stimulate the expression of proliferating cell nuclear antigen and the proliferation of aortic smooth muscle cells. Indian J Biochem Biophys 1997; 34(1-2):56-60. (Pubitemid 127431102)
99. Chatterjee S, Shi WY, Wilson P et al. Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J Lipid Res 1996; 37(6):1334-1344. (Pubitemid 26239088)
100. Ozbayraktar FB, Ulgen KO. Molecular facets of sphingolipids: mediators of diseases. Biotechnol J 2009; 4(7):1028-1041.
101. Liu YY, Han TY, Giuliano AE et al. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999; 274(2):1140-1146.
102. Liu YY, Han TY, Yu JY et al. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J Lipid Res 2004; 45(5):933-940. (Pubitemid 38552864)
103. Colell A, Morales A, Fernandez-Checa JC et al. Ceramide generated by acidic sphingomyelinase contributes to tumor necrosis factor-alpha-mediated apoptosis in human colon HT-29 cells through glycosphingolipids formation. Possible role ofganglioside GD3. FEBS Lett 2002; 526(1-3):135-141. (Pubitemid 35245708)
104. De Maria R, Lenti L, Malisan F et al. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science 1997; 277(5332):1652-1655. (Pubitemid 27446225)
105. Malisan F, Testi R. GD3 ganglioside and apoptosis. Biochim Biophys Acta 2002; 1585(2-3):179-187. (Pubitemid 36092083)
106. Hasegawa T, Sugeno N, Takeda A et al. Role of Neu4L sialidase and its substrate ganglioside GD3 in neuronal apoptosis induced by catechol metabolites. FEBS Lett 2007; 581(3):406-412. (Pubitemid 46149610)
107. Omran OM, Saqr HE, Yates AJ. Molecular mechanisms of GD3-induced apoptosis inU-1242 MG glioma cells. Neurochem Res 2006; 31(10):1171-1180. (Pubitemid 44701763)
108. Saqr HE, Omran O, Dasgupta S et al. Endogenous GD3 ganglioside induces apoptosis in U-1242 MG glioma cells. J Neurochem 2006; 96(5):1301-1314.
109. Ha KT, Lee YC, Kim CH. Overexpression of GD3 synthase induces apoptosis of vascular endothelial ECV304 cells through downregulation ofBcl-2. FEBS Lett 2004; 568(1-3):183-187.
110. Malisan F, Testi R. GD3 in cellular ageing and apoptosis. Exp Gerontol 2002; 37(10-11):1273-1282. (Pubitemid 35418286)
111. Giammarioli AM, Garofalo T, Sorice M et al. GD3 glycosphingolipid contributes to Fas-mediated apoptosis via association with ezrin cytoskeletal protein. FEBS Lett 2001; 506(1):45-50. (Pubitemid 32925229)
112. Colell A, Garcia-Ruiz C, Roman J et al. Ganglioside GD3 enhances apoptosis by suppressing the nuclear factor-kappa B-dependent survival pathway. FASEB J 2001; 15(6): 1068-1070.
113. Rippo MR, Malisan F, Ravagnan L et al. GD3 ganglioside as an intracellular mediator of apoptosis. Eur Cytokine Netw 2000; 11(3):487-488.
114. Kristal BS, Brown AM. Ganglioside GD3, the mitochondrial permeability transition and apoptosis. Ann N Y Acad Sci 1999; 893:321-324. (Pubitemid 30038096)
115. Farina F, Cappello F, Todaro M et al. Involvement of caspase-3 and GD3 ganglioside in ceramide-induced apoptosis in Farber disease. J Histochem Cytochem 2000; 48(1):57-62. (Pubitemid 30053566)
116. Scorrano L, Petronilli V, Di Lisa F et al. Commitment to apoptosis by GD3 ganglioside depends on opening of the mitochondrial permeability transition pore. J Biol Chem 1999; 274(32):22581-22585.
117. De Maria R, Rippo MR, SchuchmanEHet al. Acidic sphingomyelinase (ASM) is necessary forfas-induced GD3 ganglioside accumulation and efficient apoptosis oflymphoid cells. J Exp Medl998;187(6):897-902. (Pubitemid 28141663)
118. Hakomori SI. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. GlycoconjJ2000; 17(3-4):143-151.
119. Fredman P. Sphingolipids and cell signalling. J Inherit Metab Dis 1998; 21(5):472-480. (Pubitemid 28391500)
120. Hakomori S. Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions. J Biol Chem 1990; 265(31):18713-18716.
121. Hakomori S, Igarashi Y. Functional role of glycosphingolipids in cell recognition and signaling. J Biochem 1995; 118(6):1091-1103. (Pubitemid 26013793)
122. IdeoH, Seko A, Ishizukalet al. The N-terminal carbohydrate recognition domain of galectin-8 recognizes specific glycosphingolipids with high affinity. Glycobiology 2003; 13(10):713-723. (Pubitemid 37337052)
123. Ideo H, Seko A, Yamashita K. Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on the cell surface ofhuman colon adenocarcinoma cells. J Biol Chem 2005; 280(6): 4730-4737. (Pubitemid 40288643)
124. Kinjo Y, Wu D, Kim G et al. Recognition of bacterial glycosphingolipids by natural killer T-cells. Nature 2005; 434(7032):520-525. (Pubitemid 40477061)
125. Roche N, liver D, Angstrom J et al. Human gastric glycosphingolipids recognized by Helicobacter pylori vacuolating cytotoxin VacA. Microbes Infect 2007; 9(5):605-614. (Pubitemid 46628780)
126. Schnaar RL. Glycosphingolipids in cell surface recognition. Glycobiology 1991; l(5):477-485.
127. Lopez PH, Schnaar RL. Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol 2009; 19(5):549-557.
128. Won JS, Singh AK, Singh I. Lactosylceramide: a lipid second messenger in neuroinflammatory disease. J Neurochem 2007; 103 Suppl 1:180-191.
129. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008; 372(9647):1427-1435.
130. Nixon GF. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol 2009; 158(4):982-993.
131. Kitatani K, Sheldon K, Anelli V et al. Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. J Biol Chem 2009; 284(19):12979-12988.
132. van Eijk M, Aten J, Bijl N et al. Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation. PLoS One 2009; 4(3):e4723.
133. Vance DE. Fundamental research is the basis for understanding and treatment of many human diseases. FEBS Lett 2006; 580(23):5430-5435. (Pubitemid 44465894)
134. Sessa A, Meroni M, Battini G et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis 2001; 24 Suppl 2:66-70; discussion 65. (Pubitemid 33061634)
135. Rizk D, Chapman AB. Cystic and inherited kidney diseases. Am J Kidney Dis 2003; 42(6):1305-1317. (Pubitemid 37486778)
136. Grunfeld JP, Lidove O, Joly D et al. Renal disease in Fabry patients. J Inherit Metab Dis 2001; 24 Suppl 2:71-74; discussion 65. (Pubitemid 33061635)
137. Grunfeld JP, Lidove O.BarbeyF.HeterozygoteswithFabry's disease. Contrib Nephrol 2001; 136:208-210.
138. Christensen EI, Zhou Q, Serensen SS et al. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol 2007; 18(3):698-706. (Pubitemid 46434487)
139. Breunig F, Wanner C. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J Nephrol 2008; 21(1):32-37. (Pubitemid 351780571)
140. Sessa A, Meroni M, Righetti M et al. Autosomal recessive polycystic kidney disease. Contrib Nephrol 2001; 136:50-56.
141. Natoli TA, Smith LA, Rogers KA et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med.
142. Biswas S, Biswas K, Richmond A et al. Elevated levels of select gangliosides in T-cells from renal cell carcinoma patients is associated with T-cell dysfunction. J Immunol 2009; 183(8):5050-5058.
143. Scursoni AM, Galluzzo L, Camarero S et al. Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry. Pediatr Dev Pathol 13(1):18-23.
144. DasT, SaG, Hilston C et al. GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. Cancer Res 2008; 68(6):2014-2023. (Pubitemid 351416589)
145. Biswas K, Richmond A, Rayman P et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res 2006; 66(13):6816-6825. (Pubitemid 44085642)
146. Senda M, Ito A, Tsuchida A et al. Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: downregulation of ST6GalNAc VI in renal cancers. Biochem J 2007; 402(3):459-470. (Pubitemid 46423883)
147. Miyagi T. Aberrant expression of sialidase and cancer progression. Proc Jpn Acad Ser B Phys Biol Sci 2008; 84(10):407-418.
148. Miyagi T, Wada T, Yamaguchi K et al. Human sialidase as a cancer marker. Proteomics 2008; 8(16):3303-3311.
149. Maruyama R, Saito S, Bilim V et al. High incidence of GalNAc disialosyl lactotetraosylceramide in metastatic renal cell carcinoma. Anticancer Res 2007; 27(6C):4345-4350.
150. Sa G, Das T, Moon C et al. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T-cells. Cancer Res 2009; 69(7):3095-3104.
151. Andrews BS, Eisenberg RA, Theofilopoulos AN et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978; 148(5):1198-1215. (Pubitemid 9053639)
152. Lee HS, Lee MS, Lee SM et al. Histological grading oflgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant 2005; 20(2):342-348. (Pubitemid 40276890)
153. Vogtlander NP, van der Vlag J, Bakker MA et al. Expression of sialidase and dystroglycan in human glomerular diseases. Nephrol Dial Transplant 25(2):478-484.
154. Vogtlander NP, Visch HJ, Bakker MA et al. Ligation ofalpha-dystroglycan on podocytes induces intracellular signaling: a new mechanism for podocyte effacement?. PLoS One 2009; 4(6):e5979.
155. Miyagi T, Tsuiki S. Evidence for sialidase hydrolyzing gangliosides GM2 and GM1 in rat liver plasma membrane. FEBS Lett 1986; 206(2):223-228. (Pubitemid 16008430)
156. Kanwar YS, Farquhar MG. Detachment of endothelium and epithelium from the glomerular basement membrane produced by kidney perfusion with neuraminidase. Lab Invest 1980; 42(3):375-384. (Pubitemid 10117899)
157. Gelberg H, Healy L, Whiteley H et al. In vivo enzymatic removal of alpha 2-6-linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerular injury. Lab Invest 1996; 74(5):907-920. (Pubitemid 26152660)
158. Orlando RA, Takeda T, Zak B et al. The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin. J Am Soc Nephrol 2001; 12(8):1589-1598. (Pubitemid 32674420)
159. Andrews PM. Glomerular epithelial alterations resulting from sialic acid surface coat removal. Kidney Int 1979; 15(4):376-385. (Pubitemid 10219858)
160. Galeano B, KlootwijkR, Manoli I et al. Mutation inthe key enzyme ofsialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J Clin Invest 2007; 117(6):1585-1594. (Pubitemid 46871343)
161. Quaggin SE. Sizing up sialic acid in glomerular disease. J Clin Invest 2007; 117(6):1480-1483. (Pubitemid 46871331)
162. Ueno S, Saito S, Wada T et al. Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility. J Biol Chem 2006; 281(12):7756-7764. (Pubitemid 43847389)
163. Holthofer H, Reivinen J, Solin ML et al. Decrease ofglomerular disialogangliosides inpuromycinnephrosis ofthe rat. Am J Pathol 1996; 149(3):1009-1015. (Pubitemid 26334184)
164. Trivedi S, Zeier M, Reiser J. Role of podocytes in lupus nephritis. Nephrol Dial Transplant 2009; 24(12):3607-3612.
165. Dong L, Hu S, Chen F et al. Increased expression of ganglioside GM1 in peripheral CD4+ T-cells correlates soluble form of CD30 in Systemic Lupus Erythematosus patients. J Biomed Biotechnol 2010:569053.
166. Lacetti P, Tombaccini D, Aloj S et al. Gangliosides, the thyrotropin receptor and autoimmune thyroid disease. Adv Exp Med Biol 1984; 174:355-367.
167. Misasi R, Dionisi S, Farilla L et al. Gangliosides and autoimmune diabetes. Diabetes Metab Rev 1997; 13(3):163-179. (Pubitemid 27387464)
168. Miyamoto K, TakadaK, FurukawaK et al. Roles ofcomplex gangliosides inthe development ofexperimental autoimmune encephalomyelitis. Glycobiology 2008; 18(5):408-413. (Pubitemid 351560541)
169. Nagai Y, Momoi T, Saito M et al. Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci Lett 1976; 2(2):107-111.
170. Ponzin D, Menegus AM, Kirschner G et al. Effects of gangliosides on the expression of autoimmune demyelination in the peripheral nervous system. Ann Neurol 1991; 30(5):678-685.
171. Steck AJ, Kappos L. Gangliosides and autoimmune neuropathies: classification and clinical aspects of autoimmune neuropathies. J Neurol Neurosurg Psychiatry 1994; 57 Suppl:26-28. (Pubitemid 24356101)
172. Willison HJ. Gangliosides as targets for autoimmune injury to the nervous system. J Neurochem 2007; 103 Suppl 1:143-149.
173. Harvey SJ, Jarad G, Cunningham J et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007; 171(1):139-152. (Pubitemid 47339234)
174. Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y et al. Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. Kidney Int 2008; 74(3):289-299. (Pubitemid 352001236)
175. Rodriguez-Iturbe B, Katiyar VN, Coello J. Neuraminidase activity and free sialic acid levels in the serum of patients with acute poststreptococcal glomerulonephritis. N Engl J Med 1981; 304(25):1506-1510. (Pubitemid 11065934)
176. Laitinen L, Miettinen A, Tikkanen I et al. Glomerular sialic acid in Heymann nephritis and diacetylbenzidine induced nephropathy in rats. Clin Sci (Lond) 1985; 69(1):57-62. (Pubitemid 15032476)
177. Mosquera J, Rodriguez-Iturbe B. Extracellular neuraminidase production of streptococci associated with acute nephritis. Clin Nephrol 1984; 21(1):21-28. (Pubitemid 14222701)
178. Zador IZ, Deshmukh GD, Kunkel R et al. Arole for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J Clin Invest 1993; 91(3):797-803. (Pubitemid 23095252)
179. Morral N, Edenberg HJ, Witting SR et al. Effects of glucose metabolism on the regulation of genes of fatty acid synthesis and triglyceride secretion in the liver. J Lipid Res 2007; 48(7):1499-1510. (Pubitemid 47312012)
180. Aerts JM, Ottenhoff R, Powlson AS et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 2007; 56(5):1341-1349. (Pubitemid 46715620)
181. Zhao H, Przybylska M, Wu IH et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 2007; 56(5):1210-1218. (Pubitemid 46715599)
182. Yamashita T, Hashiramoto A, Haluzik M et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci USA 2003; 100(6):3445-3449. (Pubitemid 36356603)
183. Cheng ZJ, Singh RD, Wang TK et al. Stimulation of GLUT4 (glucose transporter isoform 4) storage vesicle formation by sphingolipid depletion. Biochem J 427(1):143-150.
184. Cohen-Forterre L, Mozere G, Andre J et al. Studies on kidney sialidase in normal and diabetic rats. Biochim Biophys Acta 1984; 801(1):138-145. (Pubitemid 14005473)
185. Cardenas A, Schadeck C, Bernard A et al. Depletion of sialic acid without changes in sialidase activity in glomeruli of uninephrectomized diabetic rats. Biochem Med Metab Biol 1991; 46(3):416-421.
186. Baricos WH, Cortez-Schwartz S, Shah SV. Renal neuraminidase. Characterization in normal rat kidney and measurement in experimentally induced nephrotic syndrome. Biochem J 1986; 239(3):705-710. (Pubitemid 17219407)
187. Boini KM, Zhang C, Xia M et al. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther 334(3):839-846.
188. Deevska GM, Nikolova-Karakashian MN. The twists and turns of sphingolipid pathway in glucose regulation. Biochimie.
189. Wennekes T, Meijer AJ, Groen AK et al. Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J Med Chem 53(2):689-698.
190. Yew NS, Zhao H, Hong EG et al. Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One 5(6):ell239.